Globalization of biomedical research -- who wins and who loses?

The move of biomedical research towards globalization is by now evident to all but those in absolute denial. Research processes are constantly broken down into their constituent services (e.g., design, data collection, statistical analysis, coordination, etc), each service being allocated to different regions of the world with the best cost-benefit ratio. In this game, wins whoever has the latest information on where the most value will be obtained by allocating a certain service to a certain group in a certain region of the globe. Of importance, the characteristics of different resources keep changing in a very dynamic fashion, and so what seems the right decision about an optimal service location for, say, data analysis might not be the right decision when the time for data analysis arrives.

Who wins and who loses in this game? Although this is widely open to discussion, it seems like those in (1) control of information and (2) able to differentiate themselves will win. In the first category, those in control of the dynamic resource information and that can guide service allocation will certainly be likely to succeed. As for those completing the different services, it seems like those with the ability to differentiate themselves while keeping a good cost-benefit ratio will win. But that is just my opinion. What is yours?